Diadema Partners’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRY
Diadema Partners's SPRY Position: Q3 2026 in Review
Diadema Partners sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 4,860 shares — an estimated $38.9K sold.
Diadema Partners first reported a position in SPRY in Q2 2026 and held it in 1 quarter. The position peaked at $38.9K in Q2 2026. 185 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.
- Diadema Partners reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Diadema Partners sold 4,860 ARS Pharmaceuticals shares in Q3 2026, an estimated $38.9K.
- Diadema Partners first reported a position in ARS Pharmaceuticals in Q2 2026 and held it in 1 quarter.
- Diadema Partners's ARS Pharmaceuticals position peaked at $38.9K in Q2 2026.
- 185 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.
Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.